The NF-κB pathway is highly active in T-ALL and is one of the major mediators of NOTCH1-induced transformation, establishing NFκB as a potentially promising target for T-ALL therapy [39]. This evidence concerns the gene NFKB1 and acute lymphoblastic leukemia.